• Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Sodium Glucose Transporter 2 Inhibitors

Sodium Glucose Transporter 2 Inhibitors

Hardcover

Series: Handbook of Experimental Pharmacology, Book 294

Medical Reference

PREORDER - Expected ship date January 17, 2027

ISBN10: 303244814X
ISBN13: 9783032448149
Publisher: Springer
Published: Jan 17 2027
Language: English

Inhibitors of the sodium glucose transporter 2 (SGLT2) such as canagliflozin, dapagliflozin, or empagliflozin were primarily developed for the treatment of diabetes. Meanwhile, they have been game changers in the treatment of conditions such as heart failure and renal failure in both diabetic and non-diabetic patients. Importantly, they do not only improve disease-specific outcomes but even reduce overall mortality by about one third. Thus, they have become game changers for indications affecting millions of people. This volume discusses their efficacy and safety with emphasis on diabetes, heart failure and renal failure. Mechanistic insight from animal studies and potential additional uses are also being discussed.

Also in

Medical Reference